Laraway Financial Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$201K Sell
7,159
-2,600
-27% -$69.2K 0.14% 124
2025
Q4
$243K Hold
9,759
0.16% 122
2025
Q3
$249K Buy
9,759
+550
+6% +$13.6K 0.17% 118
2025
Q2
$223K Hold
9,209
0.17% 116
2025
Q1
$233K Hold
9,209
0.19% 109
2024
Q4
$244K Sell
9,209
-53
-0.6% -$1.44K 0.19% 104
2024
Q3
$268K Buy
9,262
+1,159
+14% +$33.8K 0.21% 100
2024
Q2
$227K Hold
8,103
0.19% 103
2024
Q1
$225K Buy
8,103
+600
+8% +$16.6K 0.2% 104
2023
Q4
$216K Sell
7,503
-1,350
-15% -$40.8K 0.21% 102
2023
Q3
$294K Sell
8,853
-50
-0.6% -$1.77K 0.31% 81
2023
Q2
$327K Sell
8,903
-540
-6% -$21K 0.32% 82
2023
Q1
$385K Sell
9,443
-550
-6% -$23.8K 0.39% 78
2022
Q4
$512K Sell
9,993
-587
-6% -$28.1K 0.54% 62
2022
Q3
$463K Buy
10,580
+170
+2% +$8.26K 0.52% 60
2022
Q2
$546K Sell
10,410
-470
-4% -$24K 0.58% 55
2022
Q1
$563K Sell
10,880
-130
-1% -$6.75K 0.51% 65
2021
Q4
$650K Buy
+11,010
New +$546K 0.58% 59

Other funds holding PFE

Laraway Financial Advisors's PFE Position: Q1 2026 in Review

Laraway Financial Advisors reduced its Pfizer (PFE) stake by 27% in Q1 2026, selling an estimated $69.2K and leaving 7,159 shares worth $201K. The position accounts for 0.14% of the portfolio, ranked #124.

Laraway Financial Advisors first reported a position in PFE in Q4 2021 and has held it in 18 quarters since. The position peaked at $650K in Q4 2021. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Laraway Financial Advisors held 7,159 shares of Pfizer worth $201K as of Q1 2026.
  • Laraway Financial Advisors sold 2,600 Pfizer shares in Q1 2026, an estimated $69.2K.
  • Pfizer made up 0.14% of Laraway Financial Advisors's portfolio in Q1 2026, its #124 holding.
  • Laraway Financial Advisors first reported a position in Pfizer in Q4 2021 and has held it in 18 quarters since.
  • Laraway Financial Advisors's Pfizer position peaked at $650K in Q4 2021.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Laraway Financial Advisors's 13F filing for Q1 2026, filed 14 May 2026.